Lantern Pharma is advancing a new ADC program aimed at various solid tumor cancers. The program which uses a cryptophycin-based ADC has already shown very high potency in preclinical tests. 

Firefly Bio has launched with $94 million in Series A funding, introducing a novel platform utilizing degrader antibody conjugates (DACs) aimed at cancer treatment.

The U.S. FDA recently intensified its regulatory actions by issuing warning letters for manufacturing violations and the sale of counterfeit weight loss medications online. 

BioAge Labs has raised $170 million in Series D funding to enhance therapies for obesity and metabolic diseases. The round was led by Sofinnova Investments with participation from both new and existing investors. 

Bristol Myers Squibb (BMS) has partnered with deep tech company VantAI in a $674 million deal for its Generative AI-driven drug discovery platform.

Pfizer reportedly paid as much as $7 million for a 60-second commercial, leading to a finale which promoted its latest cancer initiative - LetsOutDoCancer.com.

The European Commission has approved CASGEVY™ (exagamglogene autotemcel) - the first CRISPR/Cas9 gene-edited therapy, for treating severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older.

In 2023, the biotech industry faced significant challenges, with a record number of companies, 18 in total, filing for bankruptcy, surpassing the preceding year’s record of eight.

Latigo Biotherapeutics have just announced $135 million in Series A financing to develop non-opioid medicines for patients suffering from acute and chronic pain​​.

Alys Pharmaceuticals, a novel developer of skin medications, has been established following the merger of six biotech startups, supported by a $100 million from Medicxi, a European life sciences investment firm.

News coverage of AbbVie has centered around their plan for COO Robert Michael to succeed Richard Gonzalez in July, but the company also announced it completed its acquisition of ImmunoGen, adding the ADC ELAHERE for ovarian cancer to its portfolio.

Aizon has raised $20 million in Series C financing, with NewVale Capital leading the round with support from current backers. This funding boost is set to advance their AI-based platform for pharmaceutical manufacturing and aid in deploying their latest electronic batch record (eBR) system.

Tirzepatide, Eli Lilly’s weight-loss drug most referred to by its brand names Mounjaro and Zepbound, has shown beneficial effects in relation to weight loss and glucose control. A

Further demonstrating the demand for weight loss drugs, recently published data for Amgen’s experimental obesity drug - MariTide - has shown significant weight loss within acceptable safety profiles in animal and early-stage human trials.

Catalent has been the main supplier of fill-finish and packaging services for Novo Nordisk’s Glucagon-like peptide-1 (GLP-1) syringes and injection pens, and the deal will see the sale of Catalent’s fill-finish sites in Italy, Belgium and Bloomington in the U.S. sold to Novo Nordisk, expanding its in-house manufacturing capabilities of weight loss and obesity-targeting drugs.

IGC Pharma is progressing towards a Phase 1 clinical trial for its proprietary Alzheimer's drug candidate, IGC-AD1, after demonstrating promising preclinical results.

French clinical-stage biotechnology company Vivet Therapeutics has been granted $5.3 million through the France Health Innovation Plan 2030 to support the company's pioneering work in gene therapy.

Starting a vegan or ketogenic diet can rapidly alter the immune system, a study reveals. Researchers found that switching to these diets triggers changes in the gut microbiome and immune cell populations within just four weeks.

Global pharmaceutical company, Teva Pharmaceutical, has announced plans to divest its API business, aligning with its 'Pivot to Growth' strategy. This move aims to reduce complexity and enhance profitability, whilst enabling them to focus on streamlining operations and focusing on core capabilities in generics, specialty medicines, and biopharmaceuticals.

The UK Competition and Markets Authority (CMA) is investigating Vifor Pharma over concerns of potential anti-competitive practices, focusing on the availability and affordability of essential anaemia treatments.